Discovery of a novel class of benzoxazole derivatives as histamine H3 receptor ligands for the treatment of neuropathic pain
作者:Ziying Li、Xinyi Xiao、Yulin Xue、Huiling Zhou、Chaonan Huang、Mo Zhu、Tao Zhuang、Yin Chen、Ling Huang
DOI:10.1016/j.bioorg.2022.106039
日期:2022.10
for ten other off-target receptors, and negligible effects on human ether-a-go-go-related gene (hERG, cardiac ion channel). In rodent animals, compound 8d dose-dependently reversed formalin-evoked pain (Phase I, ED50 = 6.0 mg/kg; Phase II, ED50 = 7.8 mg/kg) and CCI-induced neuropathic pain (chronic constriction injury, ED50 = 15.6 mg/kg). Furthermore, compound 8d showed an excellent safety profile in
为了发现有效的镇痛剂,我们总结了一系列针对 H 3受体 (H 3 R)的新型苯并恶唑衍生物的合成、优化和药理学抗伤害作用。在体外测定了新的苯并恶唑的组胺H 3 R 和H 1 R 结合亲和力。最佳化合物8d (2-methyl-6-(3-(4-methylpirazin-1-yl)propoxy)benzo[d]oxazole) 对 H 3 R ( K i = 19.7 nM) 表现出高亲和力,对 10其他脱靶受体,对人类 ether-a-go-go 相关基因(hERG,心脏离子通道)的影响可以忽略不计。在啮齿动物中,化合物8d剂量依赖性地逆转福尔马林诱发的疼痛(I 期,ED 50 = 6.0 mg/kg;II 期,ED 50 = 7.8 mg/kg)和 CCI 诱导的神经性疼痛(慢性缩窄性损伤,ED 50 = 15.6 mg/kg) . 此外,化合物8d在急性毒性试验(LD 50 > 2000